 SUZHOU, China and PALO ALTO, Calif., May 21, 2021 GLOBE NEWSWIRE -- Gracell Biotechnologies Inc. NASDAQ: GRCL Gracell, a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will host a conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMACD19 dual-targeting CAR-T cell therapy GC012F in relapsedrefractory multiple myeloma. This data was accepted as poster presentation at the 2021 American Society of Clinical Oncology Annual Meeting. 